Startup developing treatments for Tourette syndrome and stuttering raises $35M

It plans to invest up to $500 million a year in the areas of biopharmaceuticals, cell and gene therapy and synthetic biology, Paragon said.
https://www.google.com/url?rct=j&sa=t&url=https://www.bizjournals.com/chicago/inno/stories/fundings/2021/03/25/biotech-emalex-treating-tourettes-stuttering.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEe2jGvJ4WMWSXI9AHdxDRtZr3KpQ